Related Experiment Video
Updated: Aug 5, 2025
09:34
Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
Published on: February 9, 2019
9.0K
Solid Lipid Nanoparticles: Multitasking Nano-Carriers for Cancer Treatment
Júlia German-Cortés1, Mireia Vilar-Hernández1, Diana Rafael1,2,3
1Drug Delivery & Targeting Group, Vall d'Hebron Institut de Recerca, Universitat Autònoma de Barcelona (UAB), 08035 Barcelona, Spain.
Pharmaceutics
|March 29, 2023
Summary
Solid lipid nanoparticles (SLNs) offer a stable and effective nanotechnology approach to cancer treatment, overcoming conventional chemotherapy
Area of Science:
- Oncology
- Nanotechnology
- Drug Delivery Systems
Background:
- Conventional chemotherapy faces challenges with severe adverse effects and low specificity.
- Nanotechnology offers solutions in oncology, improving drug efficacy and delivery.
- Nanoparticle-based drug delivery systems (nanoDDS) enhance therapeutic indices and facilitate intracellular delivery.
Purpose of the Study:
- To summarize solid lipid nanoparticles (SLNs) as a promising nanoDDS for cancer therapy.
- To review SLN composition, production methods, and administration routes.
- To highlight recent studies on SLNs in cancer treatment.
Main Methods:
- Review of existing literature on SLNs and their application in cancer treatment.
- Analysis of SLN properties, including stability, targeting, and release profiles.
- Synthesis of information on production methods and administration routes.
Main Results:
- SLNs provide enhanced stability due to their solid lipid core.
- SLNs enable active targeting, sustained/controlled release, and multifunctional therapy.
- SLNs utilize biocompatible materials with scalable, low-cost production.
Conclusions:
- SLNs represent an ideal nanoDDS, meeting key requirements for cancer therapy.
- SLNs offer significant advantages over conventional chemotherapy.
- SLNs are a versatile platform for advanced cancer treatment strategies.
